Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results

被引:110
作者
Archer, David F. [1 ]
Jensen, Jeffrey T.
Johnson, Julia V.
Borisute, Hannah
Grubb, Gary S.
Constantine, Ginger D.
机构
[1] Eastern Virginia Med Sch, CONRAD Clin Res Ctr, Dept Obstet & Gynecol, Norfolk, VA 23507 USA
[2] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97239 USA
[3] Univ Vermont, Coll Med, Dept Obstet & Gynecol, Burlington, VT 05405 USA
[4] Wyeth Ayerst Res, Womens Hlth, Clin Res Dev, Collegeville, PA 19426 USA
关键词
continuous oral contraceptive; levonorgestrel/ethinyl estradiol; amenorrhea; menses inhibition;
D O I
10.1016/j.contraception.2006.07.005
中图分类号
R71 [妇产科学];
学科分类号
100211 [妇产科学];
摘要
objective: This study was conducted to evaluate the safety and efficacy of a continuous daily regimen of levonorgestrel (LNG) 90 mu g/ethinyl estradiol (EE) 20 mu g (continuous LNG/EE). Methods: Healthy women aged 18-49 years with regular menstrual cycles for 3 months enrolled in this single-treatment open-label study and took one pill of LNG 90 mu g/EE 20 mu g daily for 12 months. Results: For the 2134 subjects enrolled, the Pearl Index method failure was 1.26, and user failure was 0.34. While on Pill Pack 13, 58.7% of subjects reported amenorrhea and 79.0% reported absence of bleeding. Overall, the number of bleeding and spotting days per pill pack declined progressively. Adverse events and discontinuations were comparable to those reported for cyclic oral contraceptive (OC) regimens, except for higher rates in those related to uterine bleeding. Conclusions: Continuous LNG/EE demonstrated a good safety profile and efficacy similar to cyclic OCs. The regimen continuously inhibited menses, increased the incidence of amenorrhea over time and, except for a subset of women, decreased the number of bleeding and spotting days. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:439 / 445
页数:7
相关论文
共 14 条
[1]
A multicenter, randomized study of an extended cycle oral contraceptive [J].
Anderson, FD ;
Hait, H .
CONTRACEPTION, 2003, 68 (02) :89-96
[2]
Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives [J].
Andrist, LC ;
Arias, RD ;
Nucatola, D ;
Kaunitz, AM ;
Musselman, BL ;
Reiter, S ;
Boulanger, J ;
Dominguez, L ;
Emmert, S .
CONTRACEPTION, 2004, 70 (05) :359-363
[3]
Effect on ovarian activity of a continuous-use regimen of oral levonorgestrel/ethinyl estradiol. [J].
Archer, DF ;
Kovalevsky, G ;
Ballagh, S ;
Grubb, GS .
FERTILITY AND STERILITY, 2005, 84 :S24-S24
[4]
Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse®) [J].
Archer, DF ;
Maheux, R ;
DelConte, A ;
O'Brien, FB .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 181 (05) :S39-S44
[5]
BELSEY E M, 1991, Advances in Contraception, V7, P257, DOI 10.1007/BF01849416
[6]
Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use [J].
den Tonkelaar, I ;
Oddens, BJ .
CONTRACEPTION, 1999, 59 (06) :357-362
[7]
Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception [J].
Edelman, AB ;
Gallo, MF ;
Jensen, JT ;
Nichols, MD ;
Schulz, KF ;
Grimes, DA .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (03)
[8]
Amenorrhea associated with contraception - an international study on acceptability [J].
Glasier, AF ;
Smith, KB ;
van der Spuy, ZM ;
Ho, PC ;
Cheng, L ;
Dada, K ;
Wellings, K ;
Baird, DT .
CONTRACEPTION, 2003, 67 (01) :1-8
[9]
Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: A randomized trial [J].
Miller, L ;
Hughes, JP .
OBSTETRICS AND GYNECOLOGY, 2003, 101 (04) :653-661
[10]
Is norethisterone a lifestyle drug? Results of database analysis [J].
Shakespeare, J ;
Neve, E ;
Hodder, K .
BRITISH MEDICAL JOURNAL, 2000, 320 (7230) :291-291